EBITDA Margin % is calculated as EBITDA divided by its Revenue. Lyka Labs's EBITDA for the
three
months ended in Mar. 2026 was ₹-58 Mil. Lyka Labs's Revenue for the
three
months ended in Mar. 2026 was ₹280 Mil. Therefore, Lyka Labs's EBITDA margin for the quarter that ended in Mar. 2026 was -20.84%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Lyka Labs EBITDA Margin % Related Terms
Lyka Labs EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Lyka Labs's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:500259 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Lyka Labs's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lyka Labs EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lyka Labs's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Lyka Labs's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lyka Labs (BOM:500259) has a EBITDA Margin % of -20.84% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Lyka Labs and its competitors. According to the industry distribution chart, Lyka Labs ranks #304 out of 939 companies in the Biotechnology industry, placing it in the top 32.4%.
Is Lyka Labs' EBITDA Margin % too high?
Lyka Labs' current EBITDA Margin % is -20.84%. Based on the distribution chart, Lyka Labs ranks #304 out of 939 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Lyka Labs has a GF Score™ of 49/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lyka Labs' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lyka Labs ranks #304 out of 939 companies for EBITDA Margin %. This puts Lyka Labs in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Lyka Labs and its competitors. Lyka Labs's current EBITDA Margin % is -20.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lyka Labs stock overvalued right now?
Based on GuruFocus' analysis, Lyka Labs (BOM:500259) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹127.10, compared to a current price of ₹72.00 — trading 43.4% below its estimated fair value. The current EBITDA Margin % is -20.84%. Lyka Labs' overall GF Score™ is 49/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Lyka Labs (BOM:500259), the current EBITDA Margin % is -20.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lyka Labs (BOM:500259) Overvalued in 2026?
Based on GuruFocus' analysis, Lyka Labs stock appears to be undervalued.
The current stock price of ₹72.00 is trading 43.4% below its estimated GF Value™ of ₹127.10.
GuruFocus considers Lyka Labs to be Significantly Undervalued.
Key valuation signals for BOM:500259:
EBITDA Margin %: -20.84%
GF Value™: ₹127.10 vs. price of ₹72.00 (43.4% below fair value)
No single metric tells the full story. See the BOM:500259 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lyka Labs Ltd is an Indian biotechnology company. It mainly engages in the development of specialized formulations. The Company is engaged in only one segment which is pharmaceuticals. The Company has a presence in Domestic as well as International markets. The commercialized formulations of the company consist of hair care, anti-aging, acne management, skin lightening, face washes, sunscreens, facial scrubs, and others. It has developed a varied drug delivery system for topical steroids, painkillers, anti-fungal, and other emollients as well as liquid injectables, lyophilized injectables in the anti-bacterial, antifungal segment. The company also manufactures proton pump inhibitors, antibiotics, antifungals, steroids, etc. The majority of the company's revenue comes from India.
49GF Score
Get the complete analysis for BOM:500259
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500259 has been successfully added to your 
